SBIR/STTR Research Award

Highly efficient gas permeable cell culture devices

Award identifier 421727eb359c55753ab2d9dcd128288f6f82347f8834a9f74ae06bca387b3619Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$122,649

Program and phase

SBIR · Phase I

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
WILSON WOLF MANUFACTURING CORPORATION
Proposal award date
Not reported
Contract end date
Not reported
UEI
L1HKPVNJ33J8
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): There is an existing need for more efficient cell culture devices that retain the simplicity of traditional devices such as flasks and roller bottles. Approval of this grant will initiate the investigation of a low profile static cell culture device (LPD) that is expected to meet this need. Preliminary data shows the LPD can eliminate the gas/liquid interface present in traditional static devices, and yet still retain an extremely simple format. The LPD is expected to be an easy to use device that can maintain equivalent output as traditional flasks with a 20-fold reduction in the amount of space it occupies. That will make it substantially more efficient in terms of shipping, sterilization, storage space, incubator space, labor, and disposal cost. Importantly, the LDP is fully scalable so these advantages are captured as applications move from research to production. Two configurations of the LPD are envisioned. One has gas permeable device walls and the other does not. This investigation determines quantitatively how well each configuration compares to a commercially available tissue culture flask in biological applications using BHK and murine hybridoma cells for generation of secreted products. Our hypothesis, based upon preliminary data is that the LPD will demonstrate equivalent output as the flask when normalized for the quantity product produced per volume of space occupied by the device and when normalized for product quantity per ml of medium consumed. The LPD is particularly advantageous for applications that are subject to regulatory bodies. It is expected to provide the foundation for a far superior culture process than currently available devices can deliver. Substantial cost savings are expected to accrue from a variety of advantages including reduced facility space and complexity, more simplified process automation, reduced contamination and cross-contamination risk, reduced labor, and tighter process control capability. This is expected to be particularly helpful in cellular therapy applications and in particular, autologous cell culture applications. The overall impact of the LPD will be to cost reduce cellular therapy research and delivery to society.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

11 SBIR/STTR records share this UEI (1999–2017). Reported award amounts total $11,573,014. Reported amounts are not federal obligations.

Phases: Phase II, Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.